Genmab A/S -ADR

Genmab A/S is a biotechnology company based in Denmark. The company specialises in the design and production of antibody therapeutics for cancer treatment. It was originally founded in 1999 in Copenhagen, Denmark, with its initial public offering taking place a year later. Its headquarters can be found in Copenhagen. Operations take place across the globe, with multiple locations in the USA, the Netherland and Japan. Genmab A/S has developed a number of original products, solutions and biotechnological services. These include 5 approved therapies that have utilized Genmab innovations, as well as 4 proprietary technologies. The company has also provided innovations for over 20 products that are in development as of 2022. Since 1999, the company has contributed to 39 cumulative INDs, created through Genmab’s technology. As of August 2022, Genmab A/S employs over 1200 professionals throughout its global operations in both its offices as well as in its research centres. Genmab A/S has four subseries located in the US, the Netherlands and Japan. These subsidiaries are Genmab B.V, Genmab Holding B.V, Genmab US and Genmab K.K .The company trades its shares on the NASDAQ exchange. It trades using the stock ticker GMAB.US. To stay up to date with the financial movements of Genmab A/S, add the stock code GMAB.US to your eToro watchlist.